➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Colorcon
McKinsey
Dow
AstraZeneca

Last Updated: July 9, 2020

DrugPatentWatch Database Preview

Litigation Details for ROCHE PALO ALTO LLC v. LUPIN PHARMACEUTICALS, INC. (D.N.J. 2010)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

ROCHE PALO ALTO LLC v. LUPIN PHARMACEUTICALS, INC. (D.N.J. 2010)

Docket   Start Trial Date Filed 2010-07-14
Court District Court, D. New Jersey Date Terminated 2013-08-09
Cause 35:271 Patent Infringement Assigned To Esther Salas
Jury Demand Defendant Referred To Steven C. Mannion
Parties GILEAD PALO ALTO, INC.
Patents 6,303,607; 6,369,062; 6,479,496; 6,503,911; 6,525,057; 6,562,826; 6,617,328; 6,620,814; 6,852,724; 6,864,258
Attorneys JEFFREY S. SOOS
Firms Jackson Lewis Pc
Link to Docket External link to docket
Small Molecule Drugs cited in ROCHE PALO ALTO LLC v. LUPIN PHARMACEUTICALS, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for ROCHE PALO ALTO LLC v. LUPIN PHARMACEUTICALS, INC. (D.N.J. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-07-14 1 United States Patent Nos. 6,303,607 (“the ’607 patent”); 6,479,496 (“the ’496 patent”); 6,503,911 (“…(“the ’911 patent”); 6,525,057 (“the ’057 patent”); 6,562,826 (“the ’826 patent”); 6,617,328 (“the ’328…’328 patent”); 6,620,814 (“the ’814 patent”); 6,852,724 (“the ’724 patent”) and 6,864,258 (“the ’258 …258 patent”) (collectively the “patents-in-suit”). Plaintiffs institute this action to enforce their patent…and is the owner of the patents-in-suit, and holds all rights to said patents previously held by Syntex External link to document
2012-03-21 121 of angina—U.S. Patent Nos. 6,303,607 (“the ’607 patent”); 6,479,496 (“the ’496 patent”); 6,503,911 (…’057 patent, Cls. 1, 8, 9; ’826 patent, Cls. 16, 18; ’328 patent, Cls. 1, 5, 6, 20; ’814 patent, Cls…057 patent, Cl. 1; ’826 patent, Cls. 16, 18; ’328 patent, Cls. 10, 20; ’814 patent, Cls. 17, 19; ’724… e.g., ’911 patent, Cl. 1; ’057 patent, Cl. 1; ’826 patent, Cls. 16, 18; ’328 patent, Cls. 25, 27, …following patent claims recite “admixture”: ‘607 patent, Cl. 1; 911 patent, Cl. 1; ‘507 patent, Cl. 1; External link to document
2012-10-12 164 Asserted Claims: U.S. Patent No. 6,303,607 (“the ’607 patent”) claim 1; U.S. Patent No. 6,503,911 (“the…’911 patent”) claims 1-4; U.S. Patent No. 6,525,057 (“the ’057 patent”) claims 1-9; U.S. Patent No. … ’328 patent”) claims 1-10, 16-26, 28, 31-32; and U.S. Patent No. 6,864,258 (“the ’258 patent”) claims…2010 9 August 2013 2:10-cv-03561 830 Patent Defendant District Court, D. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
Johnson and Johnson
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.